People · Operator

Rishab K. Gupta

Named in public records as an officer, director or promoter · Biotechnology

1
Companies
1
Filings
$80.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Neogenix Oncology IncBiotechnologySeries C$80.8M$30.6M
Operator network

Rishab K. Gupta at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Peter Gordon · 4 companies · 1 sharedPeter GordonJ. Douglas Holladay · 2 companies · 1 sharedJ. Douglas Hollad…Philip Arlen · 2 companies · 1 sharedPhilip ArlenBarry Gause · 1 companies · 1 sharedBarry GauseDavid S. Moskowitz · 1 companies · 1 sharedDavid S. MoskowitzDennis Greene · 1 companies · 1 sharedDennis GreeneJames Feldman · 1 companies · 1 sharedJames FeldmanLynn Krominga · 1 companies · 1 sharedLynn KromingaMyron Arlen · 1 companies · 1 sharedMyron ArlenPhillip Arlen · 1 companies · 1 sharedPhillip ArlenRishab Gupta · 1 companies · 1 sharedRishab GuptaThomas K. Lytle · 1 companies · 1 sharedThomas K. LytleThomas Lytle · 1 companies · 1 sharedThomas LytleTimothy P. Shriver · 1 companies · 1 sharedTimothy P. ShriverWilliam Ashton · 1 companies · 1 sharedWilliam AshtonWilliam K. Ashton · 1 companies · 1 sharedWilliam K. AshtonNeogenix Oncology Inc · $80.8M raisedNeogenix Oncology IncRishab K. GuptaRG
Rishab K. Gupta Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Rishab K. Gupta on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Peter Gordon14
J. Douglas Holladay12
Philip Arlen12
Myron Arlen11
Thomas K. Lytle11
Lynn Krominga11
Barry Gause11
James Feldman11
Dennis Greene11
Rishab Gupta11
William Ashton11
Thomas Lytle11
William K. Ashton11
Phillip Arlen11
David S. Moskowitz11
Timothy P. Shriver11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.